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chemotherapy after the index date to the earliest of mean time to HSCT, death, loss 
to follow-up, or last chemotherapy dose plus 30 days. The primary endpoint was 
the percent of time in the hospital during the salvage chemotherapy period. Key 
secondary endpoints were number of hospitalisations and length of hospital stay. 
Hospitalisations associated with HSCT were excluded. Results are presented as 
mean (SD) unless indicated. Results: Twenty-two patients were included, with 
a mean age of 44 (18) years. After the index date, 19 patients died and 8 patients 
received a HSCT. During the chemotherapy salvage period, patients spent a mean 
of 56% (95% CI: 46%-69%) of their time in the hospital. There were a mean of 2.2 
(1.5) inpatient hospitalisations, 3.2 (6.2) day stays, and 1.6 (3.0) outpatient visits per 
patient, and the mean length of inpatient hospitalisation was 20.0 (20.0) days. From 
the index date to death, there were a mean of 2.8 (1.4) inpatient hospitalisations, 
4.7 (7.3) day stays, and 4.6 (7.4) outpatient visits per patient and the mean length 
of inpatient hospitalisation was 19.0 (19.0) days. ConClusions: Adult patients 
receiving salvage chemotherapy for R/R ALL in Italy spend more than half their time 
in the hospital. Costs of hospitalisations will be presented.
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objeCtives: The goal of the study was to evaluate clinical and economic feasibil-
ity of nilotinib in comparison with the imatinib usage as the first-line therapy for 
chronic myeloid leukaemia (CML), and implementation of nilotinib compared with 
imatinib in high doses in the second-line treatment. Methods: Health-economic 
analysis and budget impact analysis of the use of tyrosine kinase inhibitors (TKI) for 
CML treatment were performed in Russian economic conditions. Economic models 
for the first and the second lines of CML treatment were built separately. Results: 
Analysis showed that use of nilotinib for patients with newly diagnosed CML as the 
first-line treatment and for patients with imatinib resistance or intolerability as 
the second-line treatment is accompanied by 36% increase of consolidated budget 
expenditures in 2015 compared to 2014 in theoretical consumption calculations. In 
terms of real consumption, use of nilotinib leads to 16% increase in consolidated 
budget expenditures in 2015, in comparison with 2014. Expected budget expenditure 
in 2015, taking into account actual consumption, is 5.8 billion RUB. The growth of 
state expenditure for CML treatment might be due to increase in the number of 
patients and the use of the second-generation TKI. In case of nilotinib use, with 
consideration of remission that allows therapy cancellation, the average cost of one 
CML patient treatment based on all lines of therapy in the registry per year will be 
decreased by 6% in 2018 compared to 2015, despite an increase in the number of 
patients in the registry. ConClusions: Nilotinib is characterized by greater effi-
ciency in the both lines of therapy. Using of the second-generation TKI, including 
nilotinib, can lead to stable remission with possible therapy cancellation after two 
or three years from the moment of deep molecular response. It may lead to the 
stabilization of cost per patient in the registry by 2018.
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objeCtives: To determine time spent in the hospital by adult R/R ALL patients 
treated with current salvage chemotherapies in Germany. Methods: Adult 
patients hospitalised between 2003 and 2014 for Ph-negative R/R ALL were 
included. Eligible patients were relapsed with first remission lasting less than 
12 months, relapsed after first salvage therapy, relapsed any time after HSCT or 
refractory to primary induction or salvage therapy. Data were collected from the 
index date (first diagnosis of R/R ALL) until death or loss to follow-up. The salvage 
chemotherapy period started at the first chemotherapy after the index date to the 
earliest of mean time to HSCT, death, loss to follow-up, or last chemotherapy dose 
plus 30 days. The primary endpoint was the percent of time in the hospital dur-
ing the salvage chemotherapy period. Key secondary endpoints were number of 
hospitalisations and length of hospital stay. Hospitalisations associated with HSCT 
were excluded. Results are presented as mean (SD) unless indicated. Results: 
Twenty-one patients were included, with a mean age of 44 (16) years. After the 
index date, 17 patients died and 10 patients received a HSCT. During the salvage 
chemotherapy period, the mean percent of time spent in the hospital by patients 
was 58% (95% CI: 41%-75%). There was a mean of 1.5 (1.4) inpatient hospitalisa-
tions per patient with no day stays or outpatient visits, and the mean length of 
inpatient hospitalisation was 25 (20) days. From the index date to death, there 
were 3.5 (6.3) inpatient hospitalisations, no day stays, and 0.2 (0.6) outpatient 
visits per patient and the mean length of inpatient hospitalisation was 20 (27) 
days. ConClusions: Adult patients receiving salvage chemotherapy for R/R ALL 
in Germany spend more than half their time in the hospital. Costs of hospitalisa-
tions will be presented.
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line; meanwhile PAMI cost are around USD 1.079, 66 for the first line and USD 815, 70 
for the second one. Sc first line is USD 192, 98 per minute and USD 73, 61 per minute 
the second line for IOMA and PAMI SC USD 174, 97 per minute for the first one and 
USD 66, 74 per minute for the second one. Ratio between IV RTX cost and application 
is for IOMA 1 L 19.62 % and 14, 82 % 2 L; for PAMI the ratio for IV first line is 17, 78 % 
and for 2L 13, 44 %. SC represents IOMA 1 L 3, 18 % and 2L 1, 21 %, For PAMI is 2, 88 % 
1L and 1, 10 % 2L. El ahorro nominal por tratamiento es de USD 997, 80 para IOMA y 
de USD 904, 69 PAMI. ConClusions: nominal saving are around USD 997 for IOMA 
and 904, 69 for PAMI for treatment. IV takes 5,30 as average meanwhile SC just 27 
minutes that could improve patients quality of life.
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objeCtives: To assess hospitalization costs of patients with spinal tumors in 
France. Methods: All hospital stays with spinal tumors were extracted from the PMSI-
MCO 2012 database (French Medical Information System Program- Medicine, Surgery, 
Obstetric): ICD-10 codes C41.2 or C41.4 or C41.8 as principal/related or significantly 
associated diagnosis for primary tumors; association of ICD-10 codes C79.5 and M49.5 
as principal/related or significantly associated diagnosis or M49.5 alone as principal/
related diagnosis for secondary tumors. Patients were followed during one year from 
their first stay (e.g. March 2012/March 2013). An algorithm and a medical review excluded 
non spinal tumor related stays. Associated costs during this period were added up: a 
total annual cost (“burden”) as well as a mean annual cost per patient were estimated. 
Valuation was performed considering French official tariffs for 2012 and 2013 expressed 
in 2014 Euro. Results: 9,415 stays were extracted and considered as directly related to 
spinal tumors corresponding to 3,284 patients. Patients were 66±19 years old on average, 
55% were female. 94% of stays occurred in public hospitals. 56% of stays were ambulatory 
(length of stay, LOS = 0 day) and mean LOS associated with full hospitalizations was 
11±14 days. Spine fracture management, chemotherapy and radiotherapy accounted 
for 30%, 30% and 28% of stays, respectively. Overall, the economic annual burden of 
hospitalizations for spinal tumor reason was € 26 million; expensive drugs and implants 
funded in addition to DRGs (diagnosis related groups) accounted for 6% of this burden. 
The mean annual cost was € 7,817±8,858 per patient. ConClusions: Spinal tumors 
are mainly managed in public hospital. Hospital-related costs associated with spinal 
tumors are high. New spinal tumors treatment modalities could decrease these costs.
PCN77
healthCare BurdeN aNd eCoNomIC Cost of hosPItalIsatIoN durINg 
ChemotheraPy for adult PatIeNts wIth Ph-NegatIve B-PreCursor 
relaPsed or refraCtory (r/r) aCute lymPhoBlastIC leukaemIa (all) IN 
fraNCe
Dombret H1, Thomas X2, Chevallier P3, Nivot E4, Reitan J5, Barber BL6, Barlev A7, Mohty M8
1Hôpital Saint-Louis, Paris, France, 2Hôpital Lyon-Sud, Lyon, France, 3CHU de Nantes, Nantes, 
France, 4Amgen, Boulogne, France, 5RJM Group, Crown Point, IN, USA, 6Amgen Inc, Thousand 
Oaks, CA, USA, 7Amgen Ltd, Thousand Oaks, CA, USA, 8Hôpital Saint-Antoine, Paris, France
objeCtives: This retrospective chart review aimed to quantify hospitalisations and 
costs among adult R/R ALL patients treated with current salvage chemotherapies 
in France. Methods: Eligible patients were aged ≥ 18 years and hospitalised from 
2003-2013 for Ph-negative R/R ALL. They were relapsed with first remission lasting 
< 12 months, relapsed after first salvage therapy, relapsed any time after HSCT, or 
refractory to initial or salvage therapy. Data were collected from the index date (first 
diagnosis of R/R ALL) until death or loss to follow-up. The salvage chemotherapy 
period was defined as the first chemotherapy hospitalisation after the index date 
to the earliest of mean time to HSCT, death, loss to follow-up, or last chemotherapy 
dose plus 30 days. The primary endpoint was the percent of time in the hospital 
during the salvage chemotherapy period. A key secondary endpoint was total costs 
from index date to death. Hospitalisations and costs associated with HSCT were 
excluded. Results: Thirty-three patients were included, with mean age of 49 years 
(range 19-75). The mean proportion of time patients spent in the hospital during 
the salvage chemotherapy period was 46% (95%CI: 34%-57%). The mean number of 
inpatient hospitalisations during the salvage chemotherapy period was 2.15 (1.5), and 
mean length stay was 17 (15) days. During the salvage chemotherapy period, the mean 
(SD) cost per hospitalisation was € 31,067 (€ 4,850) and the mean hospitalisation cost 
per patient was € 66,842 (€ 46,268). From the index date to death, there was a mean of 
3.67 inpatient hospitalizations, 4.27 day hospitalizations, and 0.7 outpatient visits. 
Corresponding mean (SD) costs per hospitalisation were € 28,832 (€ 8,867), € 674 (0), and 
€ 394 (0) respectively, for a total cost per patient of € 108,967. ConClusions: Adult 
patients receiving salvage chemotherapy for R/R ALL spend approximately half their 
time in the hospital, which is associated with large reimbursement costs in France.
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objeCtives: To quantify hospitalisations among adult R/R ALL patients treated 
with current salvage chemotherapies in Italy. Methods: Adult patients hospital-
ised from 2003–2014 for Ph-negative R/R ALL were included. Eligible patients were 
relapsed with first remission lasting less than 12 months, relapsed after first salvage 
therapy, relapsed any time after HSCT or refractory to primary induction or salvage 
therapy. Data were collected from the index date (first diagnosis of R/R ALL) until 
death or loss to follow-up. The salvage chemotherapy period encompassed the first 
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month and cost/ OS month gained over control for each treatment, across the 
EU5, were then calculated. Results: Based on total OS, docetaxel consistently 
offered the lowest cost/OS month across the EU5 with a median cost of € 531/ OS 
month. For post-chemotherapy indications, Zytiga had the highest cost/OS month 
(€ 1820-€ 2904) in all countries except Italy, where Xtandi was higher (€ 3620). In 
contrast, for the pre-chemotherapy indications ,Xtandi had the highest cost/OS 
month (€ 1839 - € 4112) across the EU5. When comparing price/OS month gained 
over control, there was significant variation across products. For example, the 
EU5 median cost/OS month were significantly higher for the pre-chemotherapy 
indications for Zytiga and Xtandi (€ 12,869 and € 27,281 respectively) versus their 
post-chemotherapy indications (€ 7136 and € 6252 respectively). Jevtana’s EU5 
median cost of € 11,322, for post-chemotherapy, was comparable to the cost/OS 
month gained over control for the pre-chemotherapy indications of Zytiga and 
Xtandi. ConClusions: Payers do not equally value cost/OS month, as observed 
by the range of costs/OS month across products. Similarly, there is significant 
variation in the price/OS month gained over control, with payers paying signifi-
cantly more for the pre-chemotherapy compared to post-chemotherapy indica-
tions, inferring that payers maybe willing to pay more for treatments earlier in 
the treatment pathway for mCRPC.
PCN85
PharmaCoeCoNomICal CharaCterIstICs of dIffereNt strategIes of 
hemostasIs durINg exteNsIve hePateCtomy
Ryazhenov VV1, Maximkin SA2, Gorokhova SG3
1I.M. Sechenov First Moscow State Medical University, Moscow, Russia, 2Center for strategic 
research in healthcare, Moscow, Russia, 3Research Clinical Center of JSC Russian Railways, 
Moscow, Russia
objeCtives: To analyze budget impact and determine cost-effectiveness of differ-
ent strategies of hemostasis during hepatic resection in patients with benign and 
malignant tumors. Methods: A pharmacoeconomic model of application of differ-
ent strategies of hemostasis in target population of patients was created based on 
the data of clinical study by J. Briceño et al. (2010). Two groups of patient (100 persons 
each) were considered: 1st with tachocomb fibrin-coated collagen fleece, and 2nd 
with alternative hemostatic technologies (standard care). The calculation included 
direct costs of pharmacotherapy with different hemostatic strategies, cost of stay 
in hospital, costs of hepatectomy, and costs of blood transfusion. Results: Total 
costs were significantly lower in the group of fibrin-coated collagen fleece compared 
with the group of standard care (8,502,298.53 RUB vs. 9,243,846.02 RUB, respectively). 
Analysis of budget items showed that costs of hospitalization were 3,952,000 RUB 
in tachocomb group, and 5,200,000 RUB in the control group. In addition, the use of 
fibrin-coated collagen fleece reduced the financial costs of blood transfusion nearly 
threefold (456,146.02 RUB and 124,598.53 RUB, respectively). Cost-effectiveness ratio 
defined as a number of patients with no complications after minor or extensive 
hepatic resection was 135,938.91 and 111,872.35 in the standard care group and 
tachocomb group, respectively. ConClusions: Pharmacoeconomic advantages 
were established for the strategy with application of tachocomp fibrin-coated col-
lagen fleece during hepatectomy of patients with for benign and malignant tumors. 
The benefits were connected with lower financial costs and more favorable cost-
effectiveness.
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objeCtives: To compare the cost associated with advanced breast cancer treated 
with vinorelbine oral (VinO) versus IV (VinIV) from the national health services 
perspective in France. Methods: This was an observational, prospective, inter-
national, multicentric study. This analysis focused on French patients who were 
included in the study at the beginning of their 2nd cycle of chemotherapy with 
vinorelbine and categorized in 2 groups depending on whether they are receiving 
VinO or VinIV. In and out-patient resource utilization was collected during two 
cycles. The analysis was conducted according to the recommendations published 
by the Haute Autorité de la Santé. Results are expressed in euros 2014. The economic 
perspective is the one of the Sécurité Sociale. Results: 43 patients received VinO 
and 8 VinIV. No major difference was found between the two groups on the main 
known economics-related confounding factors. Median cost for transportation was 
lower in the VinO than in the VinIV treated patients: 85€ versus 265€ . No major out-
patient cost differences were reported on paramedical care, lab tests, imageries and 
medical visits. However, ambulatory costs (1,125€ vs 129€ ) and other drugs (287€ 
vs 85€ ) were higher for VinO chemotherapy. On the contrary, in-patient cost were 
found higher in VinIV patients (2,699€ versus 1,360€ ). Overall, patients treated with 
VinO (3,122€ ) cost less than VinIV (3,284€ ), resulting in a saving of 81€ per cycle. If 
about 10,000 cycles were to be administered in France, savings related to VinO would 
amount to 0.86m€ . ConClusions: This survey demonstrated that VinO prescribed 
in daily practice is associated with reduced hospitalization in comparison to its 
IV form and decreased cost to the Sécurité Sociale, for the same level of efficacy. 
Policies aimed at reinforcing the use of oral chemotherapy might result in saving 
to National Health Care Services.
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objeCtives: The objective of this study of breast cancer patients enrolled in the 
EMILIA clinical study was to compare costs of treating patients with either ado-
trastuzumab emtansine (T-DM1) or lapatinib plus capecitabine (L+C). Methods: 
All healthcare resource utilization (HCRU) and study drug costs for the EMILIA clini-
objeCtives: To determine the most cost-effective treatment scheme for tran-
sitional cell carcinoma of the urothelial tract (TCCU) in second line through the 
comparison of vinflunine+ best supportive care (BSC) and BSC from a payer per-
spective. Methods: Cost-effectiveness and budget impact analysis were per-
formed. Efficacy data came from phase III clinical trial. The economic perspective 
was the one of the Russian national health system. Results are expressed in RUB, 
year 2015. Sensitivity analysis were conducted to check the robustness of our find-
ings. Results: ICER was calculated: 1 114 504 RUB/18 541 EUR life-year gained (LYG). 
Budget impact analysis revealed that, a treatment with vinflunine+BSC required 
additional costs: 332 944 RUB/5 539 EUR for a 3-cycle treatment course. According 
to the budget impact analysis, shifting from a vinflunine+BSC treatment to BSC 
alone requires additional costs of 241 384 391 RUB/4 015 711 EUR for TCCU patients 
after failure of a prior platinum-containing regimen in Russia for a fulltreatment 
course. ConClusions: Vinflunine+BSC is cost-effective, as ICER does not exceed 
the willingness-to-pay threshold of Russia, which equals 1 481 749 RUB/24 651 EUR. 
And this ICER per LYG is lower than the ones calculated for the other chemothera-
pies used in oncology.
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objeCtives: To conduct a budget impact and cost effectiveness analysis of 
ferric carboxymaltose in Russian patients with colon cancer in preoperative 
period. Methods: Based on literature data (Salvadora Delgado et al. 2013, Efficacy 
of Preoperative Administration of Ferric Carboxymaltose in Colon Cancer Patients 
and Anemia) we created a pharmacoeconomic model of intravenous iron therapy 
in patients with colon cancer and anemia. The study included two groups (100 
patients each), treated with ferric carboxymaltose and placebo, respectively. The 
model included costs of medications, hospitalization and transfusions. Results: 
Total costs were 10 679 174 rub. in placebo group and 10 518 707 rub. in ferric car-
boxymaltose group. The costs of blood transfusion were 3.9 times lower in carboxy-
maltose group compared to control (placebo group); hospitalization in this group 
lasted shorter, which reduced costs 1.23 times (4 155 000 rub. and 5 100 000 rub., 
respectively). The role of cost effectiveness ratio in terms of clinical result without 
clinical complications was 132 644,50 for ferric carboxymaltose and 145 294,90 in 
placebo group. ConClusions: The application of ferric carboxymaltose in patients 
with colon cancer is justified by the comparative effectiveness estimated in budget 
impact analysis, and allows reducing costs in healthcare system.
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objeCtives: Non-Hodgkin’s lymphomas (NHLs) account for 90% of all lympho-
mas. Rituximab intravenous (IV) infusion represents a widely used therapeutic 
option against CD20-positive lymphomas. Recently, the therapeutically equivalent 
subcutaneous (SC) formulation was made available. Taking into account that SC 
formulations can result in resource and cost savings compared to IV forms of 
the same medication, this study aims to perform a cost-minimization (CMA) and 
budget-impact analysis (BIA) of introducing and switching to Rituximab SC injec-
tion for the treatment of NHLs in Greece. Methods: A questionnaire-based sur-
vey to a group of clinical practitioners that manage NHL patients formed the basis 
of the analyses. The collected data captured the resources used for the preparation 
and administration of Rituximab SC and/or IV, namely staff times, medications, 
consumables and overheads during patient stay. A CMA compared the costs of 
Rituximab SC versus IV by estimating the total cost/patient over the full course 
of treatment and the BIA estimated the impact of different penetration scenarios 
of the two formulations over a 3-year period. Calculations followed a third party 
payer perspective, according to the health system’s official price lists. Results: 
Results indicated that the SC administration provided a 77% reduction in the 
average time the nurses spent on a patient and a reduction of 90% in the time 
that the infusion chair was occupied. The average administration cost per patient 
over the full course of treatment was 13.627€ and 14.245€ for the SC and the 
IV, respectively. Budget savings for the first year of full implementation of SC 
administration was 618.708€ for a population of 1.000 patients. ConClusions: 
The outcomes suggest that the introduction of Rituximab SC in the treat-
ment of NHL could provide the grounds for efficient resource allocation within 
the hospital setting, as well as increasing maximum capacity to facilitate 
demand.
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objeCtives: There have been several recent product launches for the treatment 
of metastatic castration resistant prostate cancer (mCRPC). The aim of this study 
was to assess the cost of mCRPC treatments across the EU5 (France, Germany, 
Italy, Spain, UK) in relation to overall survival (OS), to determine if payers equally 
value the cost/ OS month for mCRPC treatments. Methods: Median OS (total and 
gain vs control arm) and average treatment duration were extracted from Phase III 
trial data for Zytiga, Xtandi, Jevtana, and docetaxel for each approved indication. 
Launch prices were extracted from publically available sources. The cost/total OS 
